The announcement follows two years of accelerated testing and regulatory navigation. Neuralink launched its first human trial in 2024, two years after the US Food and Drug Administration initially rejected its bid to begin testing on safety grounds. After the company addressed the FDA's early concerns – reportedly related to...Read Entire Article